318 related articles for article (PubMed ID: 30779338)
41. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
Gallos ID; Ganesan R; Gupta JK
Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
[TBL] [Abstract][Full Text] [Related]
42. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
43. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.
Raffone A; Travaglino A; Saccone G; Mascolo M; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):287-299. PubMed ID: 30511741
[TBL] [Abstract][Full Text] [Related]
44. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
Gallos ID; Shehmar M; Thangaratinam S; Papapostolou TK; Coomarasamy A; Gupta JK
Am J Obstet Gynecol; 2010 Dec; 203(6):547.e1-10. PubMed ID: 20934679
[TBL] [Abstract][Full Text] [Related]
45. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
Ismail MT; Fahmy DM; Elshmaa NS
Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
[TBL] [Abstract][Full Text] [Related]
47. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A; Travaglino A; Saccone G; Di Maio A; Mollo A; Mascolo M; De Rosa R; De Placido G; Insabato L; Zullo F
Gynecol Endocrinol; 2019 Nov; 35(11):932-937. PubMed ID: 31165649
[No Abstract] [Full Text] [Related]
48. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma.
Hubbs JL; Saig RM; Abaid LN; Bae-Jump VL; Gehrig PA
Obstet Gynecol; 2013 Jun; 121(6):1172-1180. PubMed ID: 23812449
[TBL] [Abstract][Full Text] [Related]
49. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
50. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
51. Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia.
Liegl S
Am Fam Physician; 2016 Jun; 93(11):948-9. PubMed ID: 27281840
[No Abstract] [Full Text] [Related]
52. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
53. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia.
Suzuki Y; Chen L; Hou JY; St Clair CM; Khoury-Collado F; de Meritens AB; Matsuo K; Melamed A; Hershman DL; Wright JD
Obstet Gynecol; 2023 May; 141(5):979-987. PubMed ID: 37023446
[TBL] [Abstract][Full Text] [Related]
54. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
55. Precancerous lesions of the endometrium and medical treatment.
Taddei GL; Bargelli G; Scarselli B; Moncini D; Scarselli G
Eur J Contracept Reprod Health Care; 1997 Dec; 2(4):239-41. PubMed ID: 9678079
[TBL] [Abstract][Full Text] [Related]
56. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia.
Matsuo K; Mandelbaum RS; Ciccone M; Khoshchehreh M; Pursuwani H; Morocco EB; Matsuzaki S; Dancz CE; Ozel B; Paulson RJ; Roman L
Int J Gynecol Cancer; 2020 Sep; 30(9):1331-1339. PubMed ID: 32376736
[TBL] [Abstract][Full Text] [Related]
57. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
[TBL] [Abstract][Full Text] [Related]
58. Endometrial hyperplasia as a risk factor of endometrial cancer.
Nees LK; Heublein S; Steinmacher S; Juhasz-Böss I; Brucker S; Tempfer CB; Wallwiener M
Arch Gynecol Obstet; 2022 Aug; 306(2):407-421. PubMed ID: 35001185
[TBL] [Abstract][Full Text] [Related]
59. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
60. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
